देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
KETOROLAC TROMETHAMINE
MINT PHARMACEUTICALS INC
M01AB15
KETOROLAC
10MG
TABLET
KETOROLAC TROMETHAMINE 10MG
ORAL
100
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0121995001; AHFS:
APPROVED
2017-02-07
_MINT-KETOROLAC_ _ _ _(Ketorolac Tromethamine Tablets) _ _Page 1 of 55 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr MINT-KETOROLAC Ketorolac Tromethamine Tablets Tablets, 10 mg, For Oral Use House Standard Non-Steroidal Anti-Inflammatory Drug (NSAID) Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Date of Initial Authorization: FEB 07, 2017 Date of Revision: November 3, 2023 Submission Control Number: 275488 _Page 2 of 55 _ _MINT-KETOROLAC_ _ _ _(Ketorolac Tromethamine Tablets) _ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 11/2023 7 WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests 11/2023 7 WARNINGS AND PRECAUTIONS, Skin 11/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant women 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................................. 6 4 DOSAGE AND ADMINISTRATION ................................................................................... 7 4.1 Dosing Considerations ............................................. पूरा दस्तावेज़ पढ़ें